Amir Iravani, MD

Nuclear Medicine

Associate Professor
Theranostics Clinical Director for Fred Hutchinson Cancer Center

Biography

Dr. Iravani is a nuclear medicine physician and an Associate Professor of Radiology at the University of Washington and the Theranostics Director at Fred Hutchinson Cancer Center. He completed Internal Medicine and Nuclear Medicine training in Australia, followed by a fellowship in Molecular Imaging and Radionuclide Therapy at the Center for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center (PMCC), Melbourne, Australia. Then he was admitted as a fellow of the Royal College of Physicians in Australia.

Research Interests

Therapeutic Nuclear Medicine and Theranostics

Molecular Imaging

Education

December 2015 – October 2016 – Fellowship – Peter MacCallum Cancer Center, Melbourne Australia

2013 – 2015 – Resident – Peter MacCallum Cancer Center, Melbourne, VIC, Australia (01/2015 – 12/25).  Nepean Hospital, Sydney, NSW, Australia (01/2014 – 12/2014). Sir Charles Gairdner Hospital Perth, WA, Australia (01/2013 – 12/2013).  Nuclear Medicine Residency. 

2008 – 2012  Resident – Sir Charles Gairdner Hospital and the affiliated hospitals, Perth, WA, Australia

2002 – 2003 – Intern – Tehran University of Medical Sciences and affiliated hospitals, Tehran, Iran

1995 – 2003  MD, Tehran University of Medical Sciences

Recent Publications (via Semantic Scholar)

PET/Computed Tomography Transformation of Oncology: Immunotherapy Assessment.
Alireza Ghodsi, Rodney J Hicks, A. Iravani - Published 2024 - PET CLINICS

An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?
Trikalinos Nikolaos A, C. Hammill, Jingxia Liu, et al. - Published 2023 - ENDOCRINE ABSTRACTS

Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios
Katerina S Konstantinoff, A. Morani, T. Hope, et al. - Published 2023 - ABDOMINAL RADIOLOGY

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial
V. Kasivisvanathan, D. Murphy, E. Link, et al. - Published 2023 - EUROPEAN UROLOGY

FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
A. Iravani, R. Wallace, S. Lo, et al. - Published 2023 - RADIOLOGY

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C. Kratochwil, W. Fendler, M. Eiber, et al. - Published 2023 - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
R. Raychaudhuri, G. Mo, Michael C. Haffner, et al. - Published 2023 - JOURNAL OF CLINICAL ONCOLOGY

SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
T. Hope, E. Antonarakis, L. Bodei, et al. - Published 2023 - JOURNAL OF NUCLEAR MEDICINE

Novel radionuclide therapy combinations in prostate cancer
A. Inderjeeth, A. Iravani, S. Subramaniam, et al. - Published 2023 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
A. Galligan, A. Iravani, A. Lasocki, et al. - Published 2023 - FRONTIERS IN ENDOCRINOLOGY